N-Acetylcysteine Therapy in an Infant with Transaldolase Deficiency Is Well Tolerated and Associated with Normalization of Alpha Fetoprotein Levels

  • Lance H. RodanEmail author
  • Gerard T. Berry
Research Report
Part of the JIMD Reports book series (JIMD, volume 31)


Transaldolase deficiency is a rare autosomal recessive disorder of the pentose phosphate pathway that presents clinically with infantile-onset hepatopathy progressing to cirrhosis, nephropathy, connective tissue abnormalities resembling cutis laxa, coagulopathy, cytopenias, and increased risk of hepatocellular carcinoma. In many cases, death occurs in infancy or early childhood. There is no established treatment for transaldolase deficiency in humans. Recent work in a knockout mouse model of transaldolase deficiency has demonstrated a benefit to supplementation with the glutathione precursor N-acetylcysteine (NAC). We describe an infant with genetically confirmed transaldolase deficiency with multisystem involvement, including liver enlargement and markedly elevated alpha fetoprotein. Acetaminophen was strictly avoided. Treatment with oral NAC over a 6-month period was well tolerated and was associated with a sustained normalization of alpha fetoprotein levels and stable clinical course. The clinical significance of normalized serum alpha fetoprotein in this patient is not certain, although it may reflect decreased hepatocyte injury and reduced hepatocarcinogenesis as has been suggested in the mouse disease model. NAC supplementation may provide benefit in humans with transaldolase deficiency. Longer follow-up and data on the response of additional patients with transaldolase deficiency to NAC supplementation will be required to further evaluate efficacy and optimize dosing.


Alpha-fetoprotein Glutathione N-acetylcysteine Pentose phosphate pathway Transaldolase deficiency 


  1. Al-Shami AM, Ben-Salem S, Hertecant J et al (2015) Transaldolase deficiency caused by the homozygous p.R192C mutation of the TALDO1 gene in four Emirati patients with considerable phenotypic variability. Eur J Pediatr 174(5):661–668CrossRefGoogle Scholar
  2. Banne E, Meiner V, Shaag A et al (2015) Transaldolase deficiency: a new case expands the phenotypic spectrum. JIMD RepGoogle Scholar
  3. Eyaid W, Al Harbi T, Anazi S et al (2013) Transaldolase deficiency: report of 12 new cases and further delineation of phenotype. J Inherit Metab Dis 36:997–1004CrossRefPubMedGoogle Scholar
  4. Hanczko R, Fernandez DR, Doherty E et al (2009) Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest 119(6):1546–1557CrossRefPubMedPubMedCentralGoogle Scholar
  5. Leduc CA, Crouch EE, Wilson A et al (2014) Novel association of early onset hepatocellular carcinoma with transaldolase deficiency. JIMD Rep 12:121–127CrossRefPubMedGoogle Scholar
  6. Viscomi C, Burlina AB, Dweikat I et al (2010) Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 16:869–871CrossRefPubMedGoogle Scholar
  7. Wamelink MMC, Struys EA, Jakobs C (2008) The biochemistry, metabolism and inherited defects of the pentose phosphate pathway. J Inherit Metab Dis 31:703–717CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Division of Genetics and GenomicsBoston Children’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations